You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
SBC: CELDARA MEDICAL, LLC Topic: NIAIDPROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline
SBC: SYNCHROHEALTH LLC Topic: NIAPROJECT SUMMARY Clinical Need: Sarcopenia and frailty represent significant and growing clinical challenges whose rates increase with age, and place patients at risk for functional decline, institutionalization, or death. Resistance exercises are strongly recommended in this age group to promote muscle regeneration and strength and are routinely a part of evidence-based home exercise programs pres ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
SBC: AQUALUNG THERAPEUTICS, CORP Topic: 300ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDPROJECT SUMMARY / ABSTRACT Drug resistance to HIV is a major threat to achieving long-term viral suppression in HIV+ individuals. Up to 16% of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes, and incomplete viral suppression and virologic failure are often associated with drug resistance. Therefore, current DHHS guideline recommends drug r ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
STING Activators as Therapy for Cancer
SBC: STINGINN, LLC Topic: 102PROJECT SUMMARY The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This signaling process is largely governed by STING (stimulator o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II
SBC: RaeSedo, LLC Topic: NHLBICurrent treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Protection of donor kidneys with synchronization modulation electric field (SMEF)
SBC: WR Biotech, LLC Topic: 400The goals of this Phase II application: 1) determine the translational significance of the i-SMEF (improved Synchronization Modulation Electric Field) in a preclinical animal model using adult Yorkshire pigs with kidney autotransplantation; and 2) determine the optimal parameters of the i-SMEF in protection against ischemic injury of the donor kidneys during cold storage and improvement of the tra ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Critical angle reflection imaging for label-free quantification of molecular interactions
SBC: BIOSENSING INSTRUMENT INC Topic: 400TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health